Clinical trial · Expanded Access
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
NCT07223606CI-TRIAL-00096938no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study uses fecal microbiota transplant (FMT) to correct gut microbiome dysbiosis prior to and during standard-of-care neuroblastoma treatment
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
| Neuroblastoma. CNS | — | UNRESOLVED | — |
| Neuroblastoma in Children | — | UNRESOLVED | — |
| Neuroblastoma (Measurable Disease) | Neuroblastoma | ONTOLOGY_EXACT | 0.85 |
| Neuroblastoma (NB) | Neuroblastoma | ONTOLOGY_EXACT | 0.85 |
| Neuroblastoma (NBL) | Neuroblastoma | ALIAS | 0.90 |
| Neuroblastoma Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fecal Microbial Transplantation | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
Show eligibility criteria text
Inclusion Criteria: * willingness of parent/guardian to sign ICF * diagnosis of neuroblastoma * dysbiosis of the gut microbiome Exclusion Criteria: * parent/guardian unwilling to sign ICF * dysbiosis does not show a bifidobaceteria-bacteroides gap * severely abnormal screening lab values
References
Publications (0)
Data not yet available
No reference posted for this study.